Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Denali Therapeutics (NASDAQ:DNLI) released its quarterly earnings results on Wednesday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08, Fidelity Earnings reports. The firm had revenue of $13.60 million for the quarter, compared to analyst estimates of $10.86 million. Denali Therapeutics had a negative return on equity of 11.03% and a negative net margin of 40.78%.

DNLI stock traded down $0.64 during midday trading on Friday, hitting $14.88. 20,224 shares of the company’s stock were exchanged, compared to its average volume of 334,047. The company has a current ratio of 10.65, a quick ratio of 10.66 and a debt-to-equity ratio of 0.15. Denali Therapeutics has a 12-month low of $14.24 and a 12-month high of $28.86. The firm has a 50 day moving average price of $15.88 and a 200-day moving average price of $19.17. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -38.67 and a beta of 2.14.

DNLI has been the topic of several recent research reports. Nomura initiated coverage on Denali Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $35.00 price target on the stock. Wedbush initiated coverage on Denali Therapeutics in a research report on Wednesday, September 25th. They set a “neutral” rating and a $19.00 price target on the stock. They noted that the move was a valuation call. BTIG Research initiated coverage on Denali Therapeutics in a research report on Friday, August 9th. They set a “buy” rating and a $30.00 price target on the stock. ValuEngine raised Denali Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Finally, Morgan Stanley set a $32.00 price objective on Denali Therapeutics and gave the stock a “buy” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. Denali Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $27.25.

In other news, COO Alexander O. Schuth sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.16, for a total value of $136,200.00. Also, CEO Ryan J. Watts sold 8,581 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $18.05, for a total value of $154,887.05. Following the completion of the sale, the chief executive officer now owns 12,505 shares of the company’s stock, valued at $225,715.25. The disclosure for this sale can be found here. 21.20% of the stock is owned by insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Earnings History for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.